文献速递流行病学与生物统计真实世界研究与卫生经济

应用方法学策略处理真实世界疫苗安全性与有效性研究中未测量混杂:一项系统综述

Application of methodological strategies to address unmeasured confounding in real-world vaccine safety and effectiveness study: a systematic review.
PubMed 文献 · J Clin Epidemiol · 2025-02-25

该系统综述检索2017年1月1日至2023年12月31日PubMed、Web of Science、Embase和Scopus中关于流感疫苗和COVID-19疫苗暴露与呼吸及心血管疾病结局的流行病学研究,共纳入913项。仅42项(4.6%)通过统计校正或混杂检测/量化处理未测量混杂,871项(95.4%)未处理但38.9%将其列为研究局限;作者认为未测量混杂仍探索不足,未来应优先开发有效方法。

要点

  • 913项真实世界疫苗研究中仅42项(4.6%)处理了未测量混杂。
  • 42项中31.0%用于统计校正,78.6%用于混杂检测或量化。
  • 阴性对照使用最多(57.1%),其次为E值(31.0%)。

核心结论

  • 真实世界疫苗安全性与有效性研究中的未测量混杂仍探索不足。
  • 当前研究主要采用混杂检测或量化方法(尤其是阴性对照和E值),未产生校正后的效应估计。
  • 部分研究使用工具变量、回归间断设计和阴性对照等校正方法,但面临严格假设的挑战。
  • 未来应优先开发有效方法以减轻未测量混杂。

研究设计与样本

  • 系统综述(PROSPERO注册号CRD42024519882),检索PubMed、Web of Science、Embase和Scopus。
  • 纳入2017年1月1日至2023年12月31日发表的、以流感疫苗和COVID-19疫苗为暴露、以呼吸和心血管疾病为结局的流行病学研究。
  • 共纳入913项研究,从合格文献中提取研究设计和统计分析数据。

主要发现

  • 913项研究中42项(4.6%,42/913)通过统计校正(31.0%,13/42)或混杂检测或量化(78.6%,33/42)处理未测量混杂。
  • 阴性对照用于24项研究(57.1%,24/42),其中2项(8.3%,2/24)用于混杂校正、22项(91.7%,22/24)用于混杂检测或量化。
  • 其他方法包括E值(31.0%,13/42)、既往事件率比(11.9%,5/42)、回归间断设计(7.1%,3/42)、工具变量(4.8%,2/42)和双重差分(2.4%,1/42)。
  • 871项研究(95.4%,871/913)未处理未测量混杂,但38.9%(355/913)将其报告为研究局限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Uses of real-world data to evaluate vaccine safety and effectiveness are often challenged by unmeasured confounding. The study aimed to review the application of methods to address unmeasured confounding in observational vaccine safety and effectiveness research. STUDY DESIGN AND SETTING: We conducted a systematic review (PROSPERO: CRD42024519882), and searched PubMed, Web of Science, Embase, and Scopus for epidemiological studies investigating influenza and COVID-19 vaccines as exposures, and respiratory and cardiovascular diseases as outcomes, published between January 1, 2017, and December 31, 2023. Data on study design and statistical analyses were extracted from eligible articles. RESULTS: A total of 913 studies were included, of which 42 (4.6%, 42/913) accounted for unmeasured confounding through statistical correction (31.0%, 13/42) or confounding detection or quantification (78.6%, 33/42). Negative control was employed in 24 (57.1%, 24/42) studies-2 (8.3%, 2/24) for confounding correction and 22 (91.7%, 22/24) for confounding detection or quantification-followed by E-value (31.0%, 13/42), prior event rate ratio (11.9%, 5/42), regression discontinuity design (7.1%, 3/42), instrumental variable (4.8%, 2/42), and difference-in-differences (2.4%, 1/42). A total of 871 (95.4%, 871/913) studies did not address unmeasured confounding, but 38.9% (355/913) reported it as study limitation. CONCLUSION: Unmeasured confounding in real-world vaccine safety and effectiveness studies remains underexplored. Current research primarily employed confounding detection or quantification, notably negative control and E-value, which did not yield adjusted effect estimates. While some studies used correction methods like instrumental variable, regression discontinuity design, and negative control, challenges arise from the stringent assumptions. Future efforts should prioritize developing valid methodologies to mitigate unmeasured confounding.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Guo J, Wang T, Cao H, et al. Application of methodological strategies to address unmeasured confounding in real-world vaccine safety and effectiveness study: a systematic review. J Clin Epidemiol. 2025. PMID: 40015486. doi:10.1016/j.jclinepi.2025.111737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。